First extended half-life rFVIII

First extended half-life rFVIII

ELOCTA® was the first extended half-life rFVIII approved by the European Commission in 20151

ELOCTA is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency) and is approved for use in all age groups and different clinical settings1

Recommended dosing

For the long-term prophylaxis with ELOCTA, the recommended dose is 50 IU/kg administered every 3-5 days.1 The dose may be adjusted based on individual response in the range of 25-65 IU/kg.1 In some cases, especially in younger patients, shorter dosing intervals or higher doses may be necessary1

Patients may be switched empirically with no need for extensive PK assessment2

People living with haemophilia should not have to compromise their lives today, but should be able to look to the future, to explore all their possibilities

IU, international unit; rFVIII, recombinant Factor VIII.


1. ELOCTA Summary of Product Characteristics. 2020.

2. Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, Quon DV, et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost. 2014 Nov;12(11):1788–800.